Cardiovascular Drugs and Therapy

, Volume 13, Issue 3, pp 265–270 | Cite as

Amiodarone Concentration in Human Myocardium After Rapid Intravenous Administration

  • Maria I. Anastasiou-Nana
  • John N. Nanas
  • George Alexopoulos
  • Joanna N. Karli
  • Zafiria J. Margari
  • Emmanouel Agapitos
  • Efrosini N. Patsi
  • Stamatios F. Stamatelopoulos


Summary. Intravenous amiodarone has been found useful in the emergent management of life-threating arrhythmias. Experimental studies have shown that its electrophysiologic effects are proportional to its myocardial concentration. However, early after its intravenous administration, the extent of the concentration of amiodarone in the human myocardium, the site of its action, is not well known. This study was performed to measure the myocardial concentration of amiodarone shortly after rapid intravenous injection. Amiodarone, 150 mg, was injected over 15 seconds intravenously into 9 patients, 52 ± 9 years of age, weighing between 65 and 98 kg (mean = 81 ± 15.6). All patients suffered from idiopathic dilated cardiomyopathy, were in NYHA functional class II, and the mean left ventricular ejection fraction was 21 ± 6%. Right ventricular endomyocardial biopsy, required for the establishment of the diagnosis, was performed 2–5 minutes after drug administration for measurements of its myocardial concentration. Plasma concentrations of amiodarone were also measured at 2, 5, 10, and 60 minutes, and measurements of right heart hemodynamics were made 2 and 10 minutes after the injection. At 2.5 ± 1.2 minutes after amiodarone administration, the mean myocardial concentration was 95.7 ± 67.4 µg/g (range, 16–175), and the myocardial/plasma amiodarone ratio was 5.05 ± 5.01. Heart rate increased from 82 ± 17 to 90 ± 13 beats/min (P < 0.05), and systolic blood pressure decreased from 132 ± 19 to 118 ± 17 mmHg (P < 0.03). The extent of myocardial fibrosis was 5.13 ± 6.55% (range, 0.3–17.5%). Intravenous amiodarone (150 mg) accumulates rapidly in the human myocardial. This pharmacokinetic characteristic probably explains its acute efficacy in the treatment of life-threatening arrhythmias.

amiodarone drug myocardial concentration drug hemodynamic effects 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997;350:1417–1424.Google Scholar
  2. 2.
    Pinto JV, Jr. Ramani K, Neelagaru S, Known M, Gheorghiade M. Amiodarone therapy in chronic heart failure and myocardial infarction: A review of the mortality trials with special attention to STAT-CHF and the GESICA trials. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina. Prog Cardiovasc Dis 1997;40:85–93.Google Scholar
  3. 3.
    Lee KL, Tai YT. Long-term low-dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias: Efficacy and safety. Clin Cardiol 1997;20:372–377.Google Scholar
  4. 4.
    Kowey PR, Marinchak RA, Rials SJ, Filart RA. Intravenous amiodarone. J Am Coll Cardiol 1997;29:1190–1198.Google Scholar
  5. 5.
    Nalos PC, Ismail Y, Pappas JM, Nyitray W, DonMichael TA. Intravenous amiodarone for short-term treatment of refractory ventricular tachycardia or fibrillation. Am Heart J 1991;122:1629–1632.Google Scholar
  6. 6.
    Ochi RP, Goldenberg IF, Almquist A, et al. Intravenous amiodarone for the rapid treatment of life-threatening ventricular arrhythmias in critically ill patients with coronary artery disease. Am J Cardiol 1989;64:599–603.Google Scholar
  7. 7.
    Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995;92:3264–3272.Google Scholar
  8. 8.
    Mooss AN, Mohiuddin SM, Hee TT, et al. Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia. Am J Cardiol 1990;65:609–614.Google Scholar
  9. 9.
    Fogoros RN, Anderson KP, Winkle RA, Swerdlow CD, Mason JW. Amiodarone: Clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation 1983;68:88–94.Google Scholar
  10. 10.
    Anastasiou-Nana MI, Anderson JL, Nanas JN, et al. High incidence of clinical and subclinical toxicity associated with amiodarone treatment of refractory tachyarrhythmias. Can J Cardiol 1986;2:138–145.Google Scholar
  11. 11.
    Mason JW. Prediction of amiodarone-induced pulmonary toxicity. Am J Med 1989;86:2–3.Google Scholar
  12. 12.
    Anastasiou-Nana MI, Levis GM, Moulopoulos SD. Pharmacokinetics of amiodarone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol 1982;20:524–529.Google Scholar
  13. 13.
    Anastasiou-Nana MI, Levis GM, Moulopoulos SD. Amiodarone: Application and clinical pharmacology in atrial fibrillation and other arrhythmias. Int J Clin Pharmacol Ther Toxicol 1984;22:229–235.Google Scholar
  14. 14.
    Levis GM, Anastasiou-Nana M, Moulopoulos S. Determination of amiodarone by high pressure liquid chromatography (HPLC). In: Turner P, Padyham C, eds. World Conference on Clin Pharm Ther, London: MacMillan, 1980, Clinical Pharmacology and Therapeutics (abstr) 0852.Google Scholar
  15. 15.
    Holt DW, Tucker GT, Jackson PR, Storey GCA. Amiodarone pharmacokinetics. Am Heart J 1983;106:840–847.Google Scholar
  16. 16.
    Venkatesh N, Somani P, Bersohn M, Phair R, Kato R, Singh BN. Electropharmacology of amiodarone: Absence of relationship to serum, myocardial, and cardiac sarcolemmal membrane drug concentrations. Am Heart J 1986;112:916–922.Google Scholar
  17. 17.
    Kannan R, Nademanee K, Hendrickson J, Rostami HJ, Singh BN. Amiodarone kinetics after oral dosages. Clin Pharmacol Ther 1982;31:438–444.Google Scholar
  18. 18.
    Anastasiou-Nana MJ, Nanas JN, Nanas SN, et al. Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: Experimental study. J Am Coll Cardiol 1994;23:253–258.Google Scholar
  19. 19.
    Nanas JN, Mason JW. Pharmacokinetics and regional electrophysiologic effects of intracoronary amiodarone administration. Circulation 1995;91:451–461.Google Scholar
  20. 20.
    Riva E, Gerna M, Neyroz P, Urso R, Bartosek I, Guaitani A. Pharmacokinetics of amiodarone in rats. J Cardiovasc Pharmacol 1982;4:270–275.Google Scholar
  21. 21.
    Talajic M, DeRoode MR, Nattel S. Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: Evidence for clinically relevant activity of the metabolite. Circulation 1987;75:265–271.Google Scholar
  22. 22.
    Maggioni AP, Maggi A, Volpi A, D'Aranno V, Tognoni G, Giani P. Amiodarone distribution in human tissues after sudden death during Holter recording. Am J Cardiol 1983;52:217–218.Google Scholar
  23. 23.
    Barbieri E, Conti F, Zampieri P, et al. Amiodarone and desethylamiodarone distribution in the atrium and adipose tissue of patients undergoing short and long-term treatment with amiodarone. J Am Coll Cardiol 1986;8:210–213.Google Scholar
  24. 24.
    Giardina EGV, Schneider M, Barr ML. Myocardial amio-darone and desethylamiodarone concentrations in patients undergoing cardiac transplantation. J Am Coll Cardiol 1990;16:943–947.Google Scholar
  25. 25.
    Nanas JN, Anastasiou-Nana MI, Margari ZJ, Karli J, Moulopoulos SD. Redistribution of amiodarone in cardiac transplant recipients treated with the drug before operation. J Heart Lung Transpl 1997;16:387–389.Google Scholar
  26. 26.
    Agapitos E, Kavantzas N, Nanas J, et al. The myocardial fibrosis in patients with dilated cardiomyopathy. Gen Diagn Pathol 1995/96;141:305–311.Google Scholar
  27. 27.
    Benotti J, Benotti N. Protein bound iodine, total iodine and butanol-extractable iodine by partial automation. Clin Chem 1963;9:408–415.Google Scholar
  28. 28.
    Connolly SJ, Latini R, Kates RE. Pharmacodynamics of intravenous amiodarone in the dog. J Cardiovasc Pharmacol 1984;6:531–535.Google Scholar
  29. 29.
    Ikeda N, Nademanee K, Kannan R, Singh BN. Electrophysiologic effects of amiodarone: Experimental and clinical observation relative to serum and tissue drug concentrations. Am Heart J 1984;108:890–898.Google Scholar
  30. 30.
    Latini R, Connolly SJ, Kates RE. Myocardial disposition of amiodarone in the dog. J Pharmacol Exp Ther 1983;224:603–608.Google Scholar
  31. 31.
    Escoubet B, Jaillon P, Berger Y, et al. Amiodarone and N-desethylamiodarone concentrations in plasma, red blood cells, and myocardium after a single oral dose: Relation to hemodynamic effects in surgical patients. Am Heart J 1986;111:280–285.Google Scholar
  32. 32.
    Plomp TA, Hauer RNW, De-Medina EOR. Amiodarone and desethylamiodarone concentrations in plasma and tissues of surgical treated patients on long-term oral amiodarone treatment. In Vivo 1990;4:97–100.Google Scholar
  33. 33.
    Escoubet B, Coumel P, Poirier JM, et al. Suppression of arrhythmias within hours after a single oral dose of amiodarone and relation to plasma and myocardial concentrations. Am J Cardiol 1985;55:696–702.Google Scholar
  34. 34.
    Haffajee CI, Love JC, Canada AT, Lesko LJ, Asdourian G, Alpert JS. Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation 1983;67:1347–1355.Google Scholar
  35. 35.
    Bandyopadhyay S, Somani P. A comparison of plasma, white blood cell, red blood cell, and tissue distribution of amiodarone and desethylamiodarone in anesthetized dogs. J Cardiovasc Pharmacol 1987;10:379–388.Google Scholar
  36. 36.
    Kannan R, Ikeda N, Wagner R, et al. Serum and myocardial kinetics of amiodarone and its desethyl metabolite after intravenous administration in rabbits. J Pharm Sci 1984;73:1208–1211.Google Scholar
  37. 37.
    Desai AD, Chun S, Sung RJ. The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med 1997;127:294–303.Google Scholar
  38. 38.
    Debbas NMG, Du Cailar C, Bexton RS, Demaille JG, Camm AJ, Puech P. The QT interval: A predictor of the plasma and myocardial concentrations of amiodarone. Br Heart J 1984;51:316–320.Google Scholar
  39. 39.
    Levine JH, Massumi A, Scheinman MM, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. J Am Coll Cardiol 1996;27:67–75.Google Scholar
  40. 40.
    Kowey PR, Levine JH, Herre JM, et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995;92:3255–3263.Google Scholar
  41. 41.
    Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study. J Am Coll Cardiol 1996;27:1079–1082.Google Scholar
  42. 42.
    Kerin NZ, Faitel K, Naini M. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs. quinidine for conversion of atrial fibrillation. Arch Intern Med 1996;156:49–53.Google Scholar
  43. 43.
    Gallik DM, Meissner MD, Communale M, Singer I, Hanin L. Favorable hemodynamic effects of Amio-Aqueous®, a new formulation of intravenous amiodarone. Circulation 1997;96:I383.Google Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Maria I. Anastasiou-Nana
    • 1
  • John N. Nanas
    • 1
  • George Alexopoulos
    • 1
  • Joanna N. Karli
    • 1
  • Zafiria J. Margari
    • 1
  • Emmanouel Agapitos
    • 1
  • Efrosini N. Patsi
    • 1
  • Stamatios F. Stamatelopoulos
    • 1
  1. 1.Department of Clinical Therapeutics, “Alexandra” HospitalUniversity of Athens School of MedicineAthensGreece

Personalised recommendations